Key Developments For icad Inc
icad Inc (ICAD.O) (Consolidated Issue listed on NASDAQ Capital Market)
iCAD, Inc. Submits VeraLook To FDA Seeking U.S. Clearance Of Computer-Aided Detection Technology For Use With CT Colonography
iCAD, Inc. announced that it has submitted data to the U.S. Food and Drug Administration (FDA) seeking 510(k) clearance of its VeraLook computer-aided detection (CAD) technology for CT colonography (CTC), or 'virtual' colonoscopy. The Company's VeraLook product uses advanced algorithms to detect and highlight potential polyps warranting closer review by a radiologist. VeraLook has the potential to reduce oversight errors that could occur during review of a virtual colonoscopy exam, due to the large number of images (approximately 1500) generated by the CT system.
iCAD, Inc. To Defer Providing Guidance On H1 2009
iCAD, Inc. announced that due to the challenging economic environment and associated uncertainty in the healthcare markets, the Company has made a decision to defer providing guidance on the first half of 2009. This decision will be reviewed mid-year and the Company will provide a further update at that time.
iCAD, Inc. Installs New Technology For Prostate MRI Image Analysis At Research Medical Center In Kansas City
iCAD, Inc. announced the installation of its VividLook Computer-Aided Detection (CAD) analysis solution for prostate MRI at Research Medical Center in Kansas City, MO. VividLook uses a complex algorithm to provide radiologists and radiation oncologists with precise information to assist in determining malignancies versus benign tumors and to pinpoint tumor location and size.
iCAD, Inc.'s PrecisionPoint, Breast MRI-Guided Interventional Planning Software Receives 510(k) Clearance
iCAD, Inc. announced it has received 510(k) clearance for PrecisionPoint, the Company's interventional planning solution for breast MRI that can make biopsies easier and faster. PrecisionPoint will be offered as an integrated module within the Company's CADvue breast MRI image review software.
iCAD, Inc. Reaffirms FY 2008 Revenue Guidance; Issues FY 2008 Net Income Guidance In Line With Analysts' Estimates
iCAD, Inc. announced that fiscal 2008 guidance remains consistent with previous guidance announced in July. The Company anticipates total revenue for fiscal 2008 to be between $38-$39 million. The Company expects net income for fiscal 2008 to be between $4.6-$5.0 million. According to Reuters Estimates, analysts were expecting the Company to report revenues of $38 million and net income of $4.6 million for the same period.
